Condition (MeSH)
Adenoma, Liver Cell
ClinicalTrials.gov lists 4 trials for Adenoma, Liver Cell or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
4 of the 4 trials are tagged with Adenoma, Liver Cell itself; the rest are tagged with a narrower condition beneath it.
When did Adenoma, Liver Cell trials start? (4)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Not applicable
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 1 |
| 2015 | 1 |
| 2011 | 1 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Adenoma, Liver Cell trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Phase 2 | 2 |
| Not applicable | 1 |
How many Adenoma, Liver Cell trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Completed | 3 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Adenoma, Liver Cell trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 1 |
Which serious adverse events do Adenoma, Liver Cell trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Rash maculo-papular | 2 | 1 |
| Aspartate aminotransferase increased | 1 | 1 |
| Blood bilirubin increased | 1 | 1 |
| Diarrhea | 1 | 1 |
| Epistaxis | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Adenoma, Liver Cell? (18)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Contrast-Enhanced Ultrasound Compared With Hepatobiliary Agent MRI for Differentiation of Focal Nodular Hyperplasia and Hepatic Adenoma: A Prospective Trial. | Ultrasound quarterly | 2024 | Yes |
| Body weight changes and duration of estrogen exposure modulate the evolution of hepatocellular adenomas after contraception discontinuation. | Hepatology (Baltimore, Md.) | 2023 | Yes |
| Benign liver tumours: understanding molecular physiology to adapt clinical management. | Nature reviews. Gastroenterology & hepatology | 2022 | Yes |
| Hepatocellular adenoma in men: A nationwide assessment of pathology and correlation with clinical course. | Liver international : official journal of the International Association for the Study of the Liver | 2021 | Yes |
| Recurrent chromosomal rearrangements of <i>ROS1</i>, <i>FRK</i> and <i>IL6</i> activating JAK/STAT pathway in inflammatory hepatocellular adenomas. | Gut | 2020 | Yes |
Showing 5 of 18 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Hepatocellular adenoma | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Hepatocellular adenoma | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Hepatocellular adenoma | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Hepatocellular adenoma | 54272 | Exact | Orphadata Science knowledge files, Product 1 |
| Hepatocellular adenoma | 54272 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.